Revolution Medicines stock analysis
Revolution Medicines (42Z) Stock Price & Analysis
42Z Stock Chart & Stats
- Day’s Range
- EUR 144.75 - EUR 148.85
- 52-Week Range
- EUR 60.00 - EUR 193.45
- Previous Close
- EUR 147.50
- Volume
- N/A
- Average Volume (3M)
- 381
- Market Cap
- EUR 31.51B
- Enterprise Value
- EUR 41.68B
- Total Cash (Recent Filing)
- EUR 3.65B
- Total Debt (Recent Filing)
- EUR 639.10M
- Price to Earnings (P/E)
- ―
- Beta
- 0.80
- Next Earnings
- Mar 01, 2027 (Est.)
- EPS Estimate
- -1.06
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
FDA-approved Commercial Product
FDA approval converts RVMD from a clinical-stage developer into a commercial oncology company with an approved oral therapy. The initial revenue base and prescription access create a durable platform for patient uptake, real-world evidence, and expansion into additional indications.
Broad RAS(ON) Development Pipeline
Multiple late-stage studies across pancreatic, lung, and colorectal cancers diversify RVMD’s product opportunity beyond one approved indication. Continued Phase 3 progress and earlier-stage RAS(ON) programs support a potentially broad, durable oncology franchise.
Strong Capital Position
A substantial cash and securities balance, supplemented by royalty financing, gives RVMD resources to fund commercialization and multiple clinical programs. This capital base provides flexibility to pursue development milestones without relying solely on near-term product revenue.
Bears Say
Heavy Cash Burn
The scale of negative operating and free cash flow shows that current commercial revenue does not yet cover development and operating needs. Continued cash burn can increase financing dependence and reduce flexibility if the company’s pipeline or launch economics develop more slowly.
Large And Rising Operating Costs
Very high operating expenses, including continued increases expected in 2027, could keep profitability out of reach even after product launch. Sustained spending on trials, commercialization, personnel, and stock compensation raises the revenue scale required to achieve durable earnings.
Uncertain Normalized Launch Economics
Initial sales benefited from finite early-launch dynamics, while future demand must increasingly come from newly eligible patients and treatment duration. Developing payer policies and higher discounts could make the long-term revenue and margin profile less predictable.
42Z FAQ
What was Revolution Medicines’s price range in the past 12 months?
What is Revolution Medicines’s market cap?
When is Revolution Medicines’s upcoming earnings report date?
How were Revolution Medicines’s earnings last quarter?
Is Revolution Medicines overvalued?
Does Revolution Medicines pay dividends?
What is Revolution Medicines’s EPS estimate?
How many shares outstanding does Revolution Medicines have?
What happened to Revolution Medicines’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Revolution Medicines?
What is the TipRanks Smart Score and how is it calculated?
Revolution Medicines Stock Smart Score
Company Description
Revolution Medicines
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mark A. Goldsmith
- Employees
- 883
- Website
- www.revmed.com
- Address
- 700 Saginaw Drive, Redwood City, CA, 94063, US
Revolution Medicines (42Z) Earnings & Revenues
42Z Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, driven by FDA approval, a rapid initial U.S. launch generating $198 million in revenue from more than 5 thousand commercial patients, broad early physician and payer access, positive regulatory progress in Europe, and continued advancement across pancreatic, lung, colorectal, and earlier-stage RAS(ON) programs. The principal challenges were that launch revenue includes finite early cohorts, normalized demand remains uncertain, formal payer policies are still developing, European approval is pending, and expenses and net loss increased substantially. Overall, the number and significance of the achievements materially outweighed the stated challenges.
View all DE:42Z earnings summaries42Z Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 1 | 13 |
| Technical Analysis | 6 | 1 | 3 |
| Moving Averages | 2 | 0 | 10 |










